Literature DB >> 25443877

Previous infection and the risk of ischaemic stroke in Italy: the IN2 study.

D Consoli1, S Vidale, U Aguglia, P Bassi, A Cavallini, F Galati, D Guidetti, N Marcello, G Micieli, G Pracucci, M Rasura, A Siniscalchi, R Sterzi, D Toni, D Inzitari.   

Abstract

BACKGROUND AND
PURPOSE: There is an increasing interest in new risk factors for ischaemic stroke. Acute and chronic infections could contribute to different aetiological mechanisms of atherosclerosis that lead to cerebrovascular disease. The aim of this study was to investigate the hypothesis that previous infections and Chlamydia pneumoniae in particular increase the risk of ischaemic stroke in the population.
METHODS: This was a prospective case-control study involving 11 Italian stroke units. Controls were age- and sex-matched with cases, represented by patients admitted to hospital for acute ischaemic stroke. For each participant classical vascular risk factors and previous inflammatory and infectious events up to 1 month before were registered. Blood samples were collected to analyse inflammatory markers and titres of antibodies against C. pneumoniae.
RESULTS: A total of 1002 participants were included (mean age 69 years) with 749 ischaemic stroke patients. Infections occurred within 1 month previously in 12% of the entire sample with a higher prevalence in the case group (14.4% vs. 3.9%). At multivariate analysis of the seropositivity of IgA antibodies against C. pneumoniae increased the risk of stroke significantly (relative risk 2.121; 95% confidence interval 1.255-3.584) and an early previous infection (up to 7 days before the event) contributed to a rise in probability of acute cerebral ischaemia (relative risk 3.692; 95% confidence interval 1.134-6.875).
CONCLUSIONS: Early previous infections and persistent chronic infection of C. pneumoniae could contribute to increase the risk of ischaemic stroke significantly, in the elderly especially.
© 2014 EAN.

Entities:  

Keywords:  Chlamydia pneumoniae; infections; ischaemic stroke; risk factors

Mesh:

Substances:

Year:  2014        PMID: 25443877     DOI: 10.1111/ene.12601

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  6 in total

1.  The influence of previous infections and antichlamydia pneumoniae seropositivity on functional outcome in ischemic stroke patients: results from the IN2 study.

Authors:  Domenico Consoli; Simone Vidale; Umberto Aguglia; Pietro Bassi; Anna Cavallini; Arturo Consoli; Franco Galati; Donata Guidetti; Giuseppe Micieli; Giuseppe Neri; Maurizia Rasura; Roberto Sterzi; Danilo Toni; Domenico Inzitari
Journal:  J Neurol       Date:  2015-03-26       Impact factor: 4.849

2.  Systemic Inflammatory Response Syndrome (SIRS) and the Pattern and Risk of Sepsis Following Gastrointestinal Perforation.

Authors:  Zhou Ye-Ting; Tong Dao-Ming
Journal:  Med Sci Monit       Date:  2018-06-09

3.  Could COVID-19 represent a negative prognostic factor in patients with stroke?

Authors:  Antonio Siniscalchi; Luca Gallelli
Journal:  Infect Control Hosp Epidemiol       Date:  2020-04-20       Impact factor: 3.254

Review 4.  Neurologic complications of COVID-19.

Authors:  Rachel Bridwell; Brit Long; Michael Gottlieb
Journal:  Am J Emerg Med       Date:  2020-05-16       Impact factor: 2.469

5.  Assessing short-term risk of ischemic stroke in relation to all prescribed medications.

Authors:  Imre Janszky; Ioannis Vardaxis; Bo Henry Lindqvist; Jens Wilhelm Horn; Ben Michael Brumpton; Linn Beate Strand; Inger Johanne Bakken; Ingvild Vatten Alsnes; Pål Richard Romundstad; Rickard Ljung; Kenneth Jay Mukamal; Abhijit Sen
Journal:  Sci Rep       Date:  2021-11-04       Impact factor: 4.379

Review 6.  Neurological consequences of COVID-19: what have we learned and where do we go from here?

Authors:  Abbas Jarrahi; Meenakshi Ahluwalia; Hesam Khodadadi; Evila da Silva Lopes Salles; Ravindra Kolhe; David C Hess; Fernando Vale; Manish Kumar; Babak Baban; Kumar Vaibhav; Krishnan M Dhandapani
Journal:  J Neuroinflammation       Date:  2020-09-30       Impact factor: 8.322

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.